» Articles » PMID: 1524909

Lymphocyte Infiltrates As a Prognostic Variable in Female Breast Cancer

Overview
Journal Eur J Cancer
Specialty Oncology
Date 1992 Jan 1
PMID 1524909
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

The predictive value of lymphocyte infiltrates (LI) was studied in 489 patients with breast cancer followed-up for over 10 years. LI were positively correlated to axillary lymph-node status, tumour diameter and histological and morphometric variables (P less than 0.001). In a multivariate analysis LI were independently related to axillary lymph-node status. LI predicted recurrence-free survival (RFS) in rapidly proliferating tumours (P = 0.0269). LI predicted RFS (P = 0.08) and breast cancer related survival (BS) (P = 0.0164) in rapidly proliferating, axillary lymph-node negative tumours. In a multivariate analysis LI independently predicted BS (P = 0.08) in rapidly proliferating tumours. LI independently predicted BS in rapidly (P = 0.025) and slowly (P = 0.09) proliferating, axillary lymph-node negative tumours. If the tumours were not categorised according to proliferation rate, LI and outcome were not significantly related. The results clearly confirm the presence of efficient immunological antitumour defence mechanisms in human breast cancer. Consequently tumour-host interactions are subject to further studies particularly in axillary lymph-node negative breast cancer.

Citing Articles

The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a review.

Andour L, Hagenaars S, Gregus B, Tokes A, Karancsi Z, Tollenaar R Virchows Arch. 2025; .

PMID: 39904885 DOI: 10.1007/s00428-025-04039-z.


Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges.

Schlam I, Loi S, Salgado R, Swain S ESMO Open. 2025; 10(2):104120.

PMID: 39826475 PMC: 11786075. DOI: 10.1016/j.esmoop.2024.104120.


Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium.

Nandi D, Sharma D Front Immunol. 2024; 15:1477980.

PMID: 39555066 PMC: 11563812. DOI: 10.3389/fimmu.2024.1477980.


T lymphocyte-derived IFN-γ facilitates breast cancer cells to pass the blood-brain barrier: An study corroborating translational data.

Pedrosa R, Kros J, Schrijver B, Berrevoets C, Marques R, van Eijck C Heliyon. 2024; 10(16):e36598.

PMID: 39262976 PMC: 11388388. DOI: 10.1016/j.heliyon.2024.e36598.


Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer.

Jama M, Tabana Y, Barakat K Eur J Med Res. 2024; 29(1):353.

PMID: 38956700 PMC: 11218087. DOI: 10.1186/s40001-024-01901-9.